Summary of Copper
Primary Information, Benefits, Effects, and Important Facts
Copper is an essential trace mineral that is used in a variety of processes in the body. The major function for copper is in catalyzing oxidation-reduction (REDOX) reactions important for the activity of a number of enzymes. Although copper is essential to health, most Western diets meet the recommended intake, making supplementation unnecessary in most healthy individuals.
Cases where copper deficiency may occur include patients who have undergone gastric bypass as well as chronic users of proton pump inhibitors, both of which interfere with copper absorption. Also, high levels of zinc intake may increase production of a protein known as metallothionein that can bind copper and reduce its levels in the body.
Although the REDOX chemistry catalyzed by copper is essential for a number of immune functions, copper also may play a role in Alzheimer's disease. Copper levels generally rise in the body with age, but seem to rise more sharply in those with Alzheimer's. Moreover, copper levels have been linked to Alzheimer's symptom severity, leading some to suggest that a lower copper intake may benefit the elderly.
No fake reviews. No selling you supplements. Just evidence-based information on what works
Our free supplement mini-course teaches you what works, what's a waste, and how to achieve your health goals.
Join the over 200,000 people who have gone through this course (saving themselves time and millions of dollars).
How to Take Copper
Recommended dosage, active amounts, other details
Supplementation of copper tends to be in the 1mg dosage, but at this moment in time there seems to be no major supplemental purpose of copper in any form. Doses of 1mg appear to be safe over the short term while higher doses should be avoided.
Get access to the latest research
By becoming an Examine.com Member, you'll have access to all of the latest nutrition research on over 300 supplements across over 500 different health goals, outcomes, conditions, and more.
Scientific Research on Copper
Click on any below to expand the corresponding section. Click on to collapse it.
Copper is an essential mineral found ubiquitously in the food supply and in drinking water. Similar to many other essential minerals in the diet it serves as a cofactor for certain enzymes, enabling these enzymes to catalyze biochemical reactions that play a role in a number of metabolic pathways.
The EPA allows up to 1.3ppm copper in human drinking water.
Copper's primary role in the body is as a cofactor for enzymes with a mineral component, known as metalloenzymes. In the case of copper-containing metalloenzymes, the copper cofactor cycles between the +1 and +2 oxidation state to catalyze important reduction and oxidation (REDOX) reactions. The use of copper as an enzyme cofactor for redox chemistry is ancient, and well-conserved throughout all domains of life; there are at least 10 distinct copper-containing proteins across prokaryotes including proteins such as NADH dehydrogenase-2, Cu,Zn-superoxide dismutase (SOD1), Cu amine oxidase, and most commonly cytochrome c oxidase.
Copper is most well known for being a vital component of the antioxidant enzyme superoxide dismutase (SOD), the major isoform being fully known as copper, zinc superoxide dismutase due to dependency on these two minerals. The major function of SOD is dismutating the toxic superoxide anion (O2-) into either oxygen or hydrogen peroxide. However, SOD also has non-specific CO2-dependent peroxidase activity, ultimately producing SOD-Cu(II)OH which then oxidizes CO2 to CO3-   which can then act as an oxidizing intermediate in cellular metabolism.
There is also another variant of this enzyme which uses manganese as its functional group (known as MnSOD) rather than copper and zinc-SOD. MnSOD has similar functions, however, the main difference being where in the body each enzyme is expressed.
Copper is an important cofactor for a number of enzymes in the body that catalyze redox reactions. The most important enzyme in so far as health claims and the effects of copper in humans is the antioxidant enzyme known as copper, zinc superoxide dismutase (Cu,Zn-SOD) where copper works in concert with zinc to transform toxic superoxide molecules into peroxide.
Copper as a free ion rather than a component of enzymes has a stimulatory role in immune cells, where a deficiency tends to lead to a suppressed response to antigens and may also suppress innate immunity, manifesting as neutropenia (a lack of neutrophils).
Beyond its role as an enzyme cofactor, copper ions appear to have a stimulatory role in the immune system. It is important to emphasize, however, that copper is an essentialtrace mineral; relatively low levels are required for optimal health and copper is inherently toxic high at high concentrations.
The recommended daily allowance (RDA) of copper in the United States is:
Requirements increase to 1,000µg (1mg) for women who are currently pregnant and a further increase to 1,300µg for women who are breastfeeding, regardless of age. The recommended intake for the elderly remains at 900µg, although some sources suggest lower intakes may be prudent.
The median intake for copper in the standard diet has been reported to be between 1,000-1,600µg (1.0-1.6mg), which sufficiently covers the RDA. The tolerable upper limit (TUL) for copper has been reported to be 10mg In otherwise healthy adults, copper intake in the range of 800µg and 1,680µg has been shown to result in similar retention in the body due fluctuating absorption rates.
The standard diets of first-world countries are sufficient to supply the recommended daily intakes of copper for all age groups.
The human body is somewhat resilient to copper deficiency due to the intestines increasing absorption of copper when bodily stores of copper drop, and copper absorption becoming more efficient with reduced dietary copper intake.
Gastric bypass surgery is thought to be a risk factor for copper deficiency, as are other gastric stressors such as gastrointestinal surgeries. Usage of proton pump inhibitors (PPIs) may also contribute to copper deficiency by reducing the ability of the body to absorb dietary copper.
Copper deficiency is relatively rare, and not a major concern for the general population. Although rare, copper deficiencies have been noted under conditions that may reduce copper absorption, such as previous gastric bypass surgery or concurrent use of proton pump inhibitors.
Some rodent studies have assessed the effects of a 'marginally' copper-deficient diet, which tends to be defined as providing approximately 25-50% of required dietary copper. For the rat, this equates to 1.5-3.0mg/kg copper, compared to 6.0-6.2mg/kg in the standard rat diet.
This low dose of copper appears to be associated with increased inflammation following an inflammatory stressor and altered cardiovascular function ranging from altered mitochondrial structure and impaired cardiac function (seen at 50% of the standard copper level) to signs of cardiomyopathy (25% of the standard copper level). There also appear to be alterations in blood flow and increases in bleeding with reduced copper intake in rats. One study also noted an upregulation of the pro-inflammatory enzyme COX-2 in rats with low copper intake.
These studies on reduced intake have noted effects that are similar to but less severe than models of true copper deficiency in rodents, where instances of substantially increased inflammation and congestive heart failure have been reported. Alterations in cardiac function prior to cardiomyopathy and cardiac hypertrophy secondary to more drastic copper deficiencies appear to be reversible following copper repletion.
In rodents given a 'marginal' copper deficiency, (50% of the standard copper intake or less) there are negative changes in immune and cardiovascular function. These changes can be normalized when copper is introduced back into the diet at sufficient levels.
True copper deficiency may result in myelopathy, which has been noted in instances following gastrointestinal surgery. Such myelopathy is known to occur in ruminants, where it is known as 'swayback' and presents in both ruminants and humans as gait ataxia and sensory symptoms. As assessed by MRI, copper deficiency myelopathy appears similar to subacute degeneration of the dorsal column in cases of Vitamin B12 deficiency.
True copper deficiency results in a neurological condition that is, to a degree, clinically similar to Vitamin B12 deficiency. This has only been noted in situations following gastrointestinal surgeries where copper absorption has been significantly impaired, however.
The copper intrauterine device (copper IUD) is a birth control device which, due to using copper in its actions, causes a small increase in serum copper concentrations in women who use the device. The 6% increase in copper noted after three months using the copper IUD was not associated with toxicity. Moreover, copper IUDs in lactating women a failed to increase copper concentrations in breast milk after six weeks.
Dietary copper tends to be bound a bound form in food products, and the acidic environment of the stomach works to free the copper from these complexes. Copper can be absorbed through stomach tissue although when fed to rats via gastric intubation it has failed to appreciably be absorbed via the stomach wall.
It has been argued that food-bound copper is processed differently than copper in the water supply or via dietary supplements; copper can appear rapidly in the blood as free copper (see distribution section) bypassing oral metabolism when not in foodbound form, while acid-mediated digestion of copper from food products allows it to be processed by the liver.
The acidity of the stomach plays a role in extracting dietary copper sources from foodstuffs so that free copper can be absorbed in the intestines.
Copper is absorbed in the intestines from the same transporter as zinc, known as zinc transporters (ZnTs), as well as a common bivalent cation transporter known as DMT1 that also mediates absorption of other minerals. Copper also has its own transporter known as the copper transporter 1 (CRT1) which can also mediate zinc and iron transportation. When copper is complexed with amino acids, amino acid transporters may also play a role in copper absorption.
The overall absorption of copper from the diet tends to be approximately 30-40% although it is estimated to range between 12-67% reflecting dietary copper levels (better absorption with low intake, worse absorption with progressively higher intakes of copper). Copper absorption also tends to vary from person to person, as differences have been noted among individuals even with the same amount of copper in the diet.
Copper can be absorbed from the intestines using a variety of different transporters, with the three groups of transporters (zinc transports, copper transports, and generalized bivalent cation transporters) also mediating iron and zinc absorption.
High levels of zinc in the intestines can promote the synthesis of a binding protein known as metallothionein which also binds to copper; this mechanism leads to high doses of zinc reducing copper absorption. Copper also has the potential to induce metallothionein proteins, in a process known as mutual antagonism. Because copper intake is much lower relative to zinc, copper is typically not taken in amounts that would interfere with zinc absorption, however.
The induction (responsive production) of the protein metallothionein is a protective mechanism that attenuates absorption of zinc or copper at high concentrations, reducing the risk of harm from mineral overdoses. High concentrations of either mineral can induce this protein, raising the potential for one mineral to cause deficiencies of the other by preventing absorption. On a practical level, copper-induced zinc deficiencies have not been reported due to the low amount of copper present in the diet relative to zinc. Excessive zinc intake is a well-known cause of copper deficiency, however.
The addition of phytate to the diet has failed to influence copper absoprtion in man although high levels of phytate in the rat show the expected reduction in bodily retention of copper over a prolonged period of time.
When looking at how other dietary components can influence absorption of copper in both rodents and humans, it seems that high protein diets increase copper absorption in both rodents and humans (150g protein compared to 50g) resulting in lower copper requirements with higher protein intakes. Composition of the protein sources may also be relevant, as raw meat products have been noted to induce copper deficiency in rats whereas cooked meats have not been shown to have this effect. The general idea of increased dietary protein promoting greater retention of copper may also be a more general mechanism that applies to other dietary minerals as well.
In regard to dietary factors that can interact with copper absorption, high protein diets tend to promote copper absorption while higher than normal intakes of phytic acid may reduce absorption. These alterations in absorption are similar for most other divalent cations including calcium and magnesium.
When present in the blood, around 85-95% of copper is bound to the main transportation protein known as ceruloplasmin where it is referred to as 'bound' copper. In contrast, the remaining 5-15% of copper is more loosely bound to albumin and is termed 'free copper'. Free copper levels are more biologically relevant since they can dissociate easier and act in nearby tissues. Diseases associated with high copper accumulation in tissue (ex. Wilson's Disease) are at times due to reduced ceruloplasmin levels, causing an increase in free copper (this is not the only explanation, however). Outside of Wilson’s disease, more moderate increases in free copper are still thought to be harmful and a potential cause of toxicity.
The majority of copper found in circulation is tightly bound to the primary binding protein known as ceruloplasmin, with the remaining amount of copper, known as free copper, more loosely associated with albumin. Significant increases in free copper are considered a risk factor for toxicity.
The overall copper content of an average human body (70kg body weight; approximately 110mg copper) tends to be 6% total copper circulating in the blood and another 9% within the brain, with the remaining 85% being stored in peripheral tissue. Among the peripheral tissues, 47% of total body copper is located in bone and connective tissue while 27% is in skeletal muscle and the remaining copper is stored in the liver.
Copper can contribute to oxidative stress, which may play a role in the development of anxiety disorders. Furthermore, copper is known to inhibit the GABAA receptor, and GABAergic transmission is known to play a role in anxiety and depression.
Copper levels have been found to be significantly higher in a sample of Bangladeshi patients with generalized anxiety disorder (GAD) than healthy controls. Those with GAD had similar socioeconomic characteristics to the controls, which may suggest that nutritional differences may not explain the differences in copper levels. Higher levels of copper in those with anxiety compared to controls were found in a second study. These patients were then treated with antioxidant therapy for a minimum of 8 weeks, along with zinc and magnesium and manganese if warranted, which reduced anxiety although it did not have a significant effect on serum copper levels.
Serum copper levels are consistently higher in patients with unipolar depression, even after successful treatment, thus suggesting that serum copper levels may be a "trait marker" for depression. Copper levels have also been shown to correlate with depression levels in shift nurses and post-partum depression.
Another study found that patients with depression had higher levels of serum copper compared to controls which was treated with a combination of antioxidant therapy and zinc for 8 weeks; depression did not respond to this treatment, nor did copper serum levels did not change post-treatment.
The heart tissue of people who have died of ischemic heart disease tend to be low in copper. Furthermore, enzymes which play a role in cardiovascular health through the rebuilding and maintenance of cardiovascular tissue, such as lysyl oxidase which helps crosslink arterial collagen and elastin, depend on copper. Another copper-dependent enzyme, copper-zinc superoxide dismutase, plays a role in the antioxidant capacity of tissues throughout the body and has also been suggested to play a role in a cardiovascular health. These facts together provide an observational and mechanistic rationale for a possible role of copper supplementation in cardiovascular health.
However, several observational studies have noted that blood copper levels may actually be associated with cardiovascular disease. One cohort study found that increased ceruloplasmin levels (which is a major protein which carries copper in the blood) was correlated with an increased risk of heart attack. An analysis of the Second National Health and Nutrition Examination Survey which directly measured serum copper also found that increased serum copper was associated with an increased risk for cardiovascular disease.
The heart tissue of people with heart disease tends to be low in copper. However, people with heart disease also tend to have higher levels of copper in the blood.
There have been a few clinical trials to date specifically looking at how copper affects heart tissue and markers of cardiovascular disease.
One study found that administering a copper chelator, which would be expected to bind copper in the blood, decreased hypertrophy of the left ventrical in patients with type 2 diabetes; urinary copper excretion due to chelation was found to be associated with better outcomes. The phenomenon of high serum copper levels has been noted in an observational study involving elderly patients with left ventricular hypertrophy.
In terms of copper supplementation, one randomized placebo-controlled trial found no effect on C-reactive protein, homocysteine, and cholesterol when supplementing patients with moderately high blood cholesterol with 2mg copper per day for 8 weeks. A randomized crossover trial in healthy young women treated with 0, 3, or 6mg copper for 4 weeks per period found no effect on several markers for cardiovascular disease except for a 30% reduction in plasminogen activator inhibitor type 1, a risk factor for thrombosis and atherosclerosis, with 6mg of copper.
A copper chelator has been noted to help mitigate left ventricular hypertrophy in patients with type 2 diabetes. Copper supplementation has not been seen to have much effect on cardiovascular risk markers over the short term in clinical trials.
Serum copper is elevated in those with atherosclerosis, and there seems to be a dose-response relationship: higher serum copper levels correlate with more severe coronary artery disease. Higher copper levels in the arterial wall of those with atherosclerosis has also been observed.
A randomized crossover trial in healthy young women treated with 0, 3, or 6mg copper for 4 weeks per period found that 6mg of copper for 4 weeks led to a 30% reduction in plasminogen activator inhibitor type 1, which is a risk factor for atherosclerosis.
People newly-diagnosed with essential hypertension had lower plasma copper levels compared to people with normal blood pressure who were matched for age.
A randomized crossover trial in healthy young women treated with 0, 3, or 6mg copper for 4 weeks per period found a 30% reduction in plasminogen activator inhibitor type 1 with 6mg of copper.
One randomized placebo-controlled trial found no effect on total, HDL, or LDL cholesterol when supplementing healthy middle-aged people with moderately high blood cholesterol with 2mg copper per day for 8 weeks. Similar null results on blood cholesterol were found when men with moderately high blood cholesterol were supplemented with 2mg copper per day for 4 weeks in a crossover trial. Another trial in healthy men taking 8mg copper supplementation for 6 months found no effect on plasma lipid profile, either.
Copper supplementation of up to 6mg per day does not seem to have an effect on the susceptibility of LDL to oxidation in vitro.
Clinical trial evidence to date suggests that copper supplementation has no effect on plasma lipid profile.
While a deficiency of copper tends to result in impaired glucose metabolism and alterations in lipid metabolism phenotypically similar to that of type II diabetes, serum concentrations of copper are generally unaltered in naturally-occurring type II diabetes when compared to healthy controls or slightly increased. A decrease in red blood cell concentration of copper may occur and due in part due to reductions in serum zinc during the pathogenesis of type II diabetes the copper:zinc ratio is increased.
Copper is present in the retina where it functions in REDOX balance as a cofactor for the enzyme copper, zinc-superoxide dismutase. Similar to other minerals involved in the catalytic activity of antioxidative enzymes, copper exerts protective effects by functioning as an enzyme cofactor, but can also induce oxidative toxicity at high doses.
Copper concentrations in the human retina are generally an order of magnitude lower than zinc concentrations when assessed posthumously, ranging between 0.2-9nM/mg (retina), 0.4-7nM/mg (RPE; retinal pigment epithelium), and 0.6-4.2nM/mg (choroid) dry weight. The changes in copper seem to be similar to changes in zinc, increasing in the choroid during the aging process (with minimal changes in the retina and RPE. There also appears to be some sex differences, with zinc being higher in the male choroid (no difference between zinc and copper in females) and copper higher in the RPE of women. Cadmium, which is not present in this tissue at birth but increases with age seems to also accumulate in the eye alongside copper and zinc with some sex differences.
Copper is present in all regions of the eye where it works with zinc as a cofactor for the enzyme Cu,Zn-superoxide dismutase.
Due to the role of other essential minerals that are involved in oxidative processes in the retina (Zinc and Selenium in particular), copper is also thought to play a role in oxidative pathology of the retina, namely age-related macular degeneration. Copper has been added to some compound formulations for age-related macular degeneration (AREDS at 2mg) to avoid copper-deficiency, which is thought to be a risk with zinc supplementation. There do not appear to be any studies on copper in isolation, however.
At this moment in time there is no evidence to assess the role of copper specifically in age-related macular degeneration. It has been included alongside zinc in some formulations for precautionary measures.
Copper is implicated in the function of neutrophils.
Marginal copper deficiency (25% of the copper-sufficient diet) appears to promote neutrophil accumulation in liver tissue following an inflammatory response in rats, whereas more extensive deficiency has been shown to activate neutrophils. Both neutrophil accumulation and activation contribute to the development of inflammation.
Copper is known to play an important role in several cell signaling pathways important for the immunological function of macrophages. In macrophages that have been activated by inflammatory cytokines, copper levels tend to increase, while copper deficiency has been shown to impair their immunological function. Moreover, copper deficiency in animals has been correlated with increased susceptibility to bacterial infections.
The mechanism by which copper enhances the macrophage immune-response has only recently been uncovered. As part of the innate immune response, activated macrophages (and neutrophils) engulf invading pathogens such as bacteria into membrane-bound phagosomes in a process called phagocytosis. The respiratory burst reaction inside phagosomes generates toxic reactive oxygen species (ROS) to kill invading pathogens while protecting the rest of the cell from damage. Copper has recently been found to play an important role in this process, where elevated intracellular copper levels in macrophages causes the copper transporter protein ATP7A to relocate to phagosomes, delivering additional copper ions that are thought to enhance the ROS-generating ability of the respiratory burst reaction.
By increasing ROS production within phagosomes, copper plays an important role in the ability of macrophages and neutrophils to kill invading pathogens.
Copper is known to play a role in differentiation and proliferation of dermal papilla cells (DPCs), a special type of fibroblast cell that is involved in hair growth. In vitro administration of a tripeptide containing copper (at 1µM) appears to promote DPC proliferation, while promoting the growth and elongation of human hair follicles.
In subjects with hair loss, although Zinc seems to be lower relative to controls with no hair loss, serum concentrations of copper are unaltered. The lone study assessing copper levels in hair itself (in men with androgenic alopecia) noted reduced concentrations relative to those without hair loss.
The copper intrauterine device (IUD) is an implantable device in women which utilizes copper to exert an antifertility effect either acutely as emergency contraceptive or for more prolonged periods of time with efficacy.
Women who use a copper IUD may experience bleeding irregularities within the first six months of usage that may promote discontinuation of the IUD; these irregularities may be treated by the likes of NSAIDs and other drugs. Usage of the contraceptive may increase serum copper levels slightly (up to 6%), which is not thought to be toxic. Use of a copper IUD has not been shown to affect copper concentrations in breast milk.
Copper IUDs may increase serum copper concentrations, but it is to a small degree and currently not thought be a significant health factor.
Copper is thought to contribute to Alzheimer's Disease (AD) since alterations in copper levels tend to precede symptoms of AD in some, but not all patients. Generally subjects with AD have higher serum but not cerebrospinal fluid (CSF) copper concentrations than otherwise healthy controls and copper is implicated in the disease mostly due to its correlation with the time-course of Alzheimer's (prevalence increasing in the last half decade) in developed nations using copper plumbing. Increased free copper levels, while sometimes elevated only slightly, are prevalent enough in those with AD relative to healthy controls that this has been termed the "copper phenotype".
Although copper concentrations tend to be increased in the brain during the normal aging process in both serum and the brain, preexisting symptoms of AD can be exacerbated by long-term dietary copper exposure, and copper chelators that decrease free copper levels can be therapeutic in mouse models. Given the plausible role for copper in the pathology of AD, and plenty of aforementioned “circumstantial” evidence, it has been recommended that the elderly avoid multivitamins containing added copper and also consider diets with lower copper levels.
Although copper concentrations in the body naturally become elevated during the aging process, levels tend to be higher in subjects with symptoms of Alzheimer's disease. Copper seems to be associated with worsening of symptoms and may have a causative role, suggesting that the elderly may benefit from reducing copper intake from food and supplements.
When looking at in vitro evidence, it seems that copper itself can induce oxidative stress in neurons in a manner modulated by amyloid precursor proteins (APPs). A prevailing theory is that by binding to amyloid beta (Aβ), a peptide derived from from APP, copper to undergoes redox cycling that produces peroxide, a possible driver of the oxidative-stress associated with AD pathology.
ATP7B is a gene that controls 'free' copper levels (copper in the body that is not bound to the primary copper-binding protein ceruloplasmin) and its dysfunction explains Wilson's disease. Thus, it was hypothesized that variations in ATP7B activity could also partially explain AD occurrence. Supporting this idea, it has been reported that ATP7B SNPs that affect the affinity of ceruloplasmin for copper differ between AD patients and age-matched healthy controls.
The presence of certain mutations (SNPs) in ATP7B can increase free copper levels by reducing the binding affinity of ceruloplasmin. Certain ATP7B SNPs have recently been found to be more prevalent in those with Alzheimer’s disease (AD), suggesting that changes in genes that affect copper handling may confer a genetic susceptibility to AD.
Zinc is a dietary mineral with shared metabolism and regulation with copper. Proteins known as metallothioneins exist which serve to sequester minerals and limit their activity through binding to them. These proteins are so important for metal ion regulation that they are expressed in almost all forms of life, from bacteria and fungi to plants and eukaryotes. The major site of metallothionein biosynthesis is in the liver and kidneys, where they are are normally expressed at low levels, which limits their activity, but are increased in response to elevated concentrations of zinc or copper. By binding to and regulating the concentration of essential minerals such as zinc and copper, metallothioneins limit cellular toxicity and regulate a number of metal ion-dependent physiological processes including transcription, metabolism, and the control of protein synthesis.
Metallothionein gene expression is regulated by the transcription factor metal-regulatory transcription factor 1 (MTF-1), which is activated by zinc or copper as well as toxic heavy metals including cadmium and mercury. By binding to and sequestering heavy metals, metallothioneins also play an important role in limiting heavy metal toxicity.
Metallothioneins can be found in the intestines, where high oral doses of zinc (600mg or greater) increase their expression, which appears to be a protective response to limit zinc toxicity. Because metallothioneins bind minerals indiscriminately, this can cause reduced absorption of other minerals such as copper and is known to induce copper deficiencies, a potential cause of CNS demyelination and/or death.
High doses of zinc are known to induce metallothioneins which can bind to copper and prevent its absorption. At the extreme, this could potentially cause copper deficiencies resulting in cognitive impairments and potentially death. It is unlikely that standard supplemental doses of zinc (15-50mg) are sufficient to cause such symptoms, however, as all known cases of zinc-induced copper deficiency were the result of accidental zinc overdoses or 500mg or greater.
High dietary protein intake (150g in an adult male) has been shown to increase copper retention, although individual amino acids can have positive or negative effects in isolation. L-histidine has shown an inhibitory effect on copper retention while other amino acids like Glycine, L-tryptophan, and L-methionine have been shown to promote it. The ability of protein to affect copper levels is thought to be related to the affinity of individual amino acids for copper ions, which can function as ligands to transport copper across cellular membranes for absorption. L-cysteine can reduce copper absorption by reducing divalent copper to a less absorbed, monovalent state, a mechanism similar to Vitamin C-mediated suppression of copper absorption. Binding of divalent copper to amino acid ligands attenuates the inhibitory effect of cysteine or vitamin C on absorption.
Copper is known to have a variety of interactions at the level of the intestines with amino acids that can affect absorption in a positive and negative manner. From a practical standpoint, the effects of increased dietary protein consumption (from food) seem to cause the pro-absorptive mechanisms to win out; increased protein intake has been shown to promote copper absorption.
- Subar AF1, et al. Dietary sources of nutrients among US adults, 1989 to 1991. J Am Diet Assoc. (1998)
- Sadhra SS1, Wheatley AD, Cross HJ. Dietary exposure to copper in the European Union and its assessment for EU regulatory risk assessment. Sci Total Environ. (2007)
- Abdel-Mageed AB1, Oehme FW. A review of the biochemical roles, toxicity and interactions of zinc, copper and iron: II. Copper. Vet Hum Toxicol. (1990)
- Copper in Drinking Water.
- Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc.
- Ridge PG1, Zhang Y, Gladyshev VN. Comparative genomic analyses of copper transporters and cuproproteomes reveal evolutionary dynamics of copper utilization and its link to oxygen. PLoS One. (2008)
- Liochev SI1, Fridovich I. Mechanism of the peroxidase activity of Cu, Zn superoxide dismutase. Free Radic Biol Med. (2010)
- Tainer JA, et al. Structure and mechanism of copper, zinc superoxide dismutase. Nature. (1983)
- Getzoff ED, et al. Electrostatic recognition between superoxide and copper, zinc superoxide dismutase. Nature. (1983)
- Liochev SI1, Fridovich I. CO2, not HCO3-, facilitates oxidations by Cu,Zn superoxide dismutase plus H2O2. Proc Natl Acad Sci U S A. (2004)
- Chen SN, Hoffman MZ. Rate constants for the reaction of the carbonate radical with compounds of biochemical interest in neutral aqueous solution. Radiat Res. (1973)
- Medinas DB1, et al. The carbonate radical and related oxidants derived from bicarbonate buffer. IUBMB Life. (2007)
- Manganese superoxide dismutase, MnSOD and its mimics.
- Liochev SI1, Fridovich I. Carbon dioxide mediates Mn(II)-catalyzed decomposition of hydrogen peroxide and peroxidation reactions. Proc Natl Acad Sci U S A. (2004)
- Blakley BR, Hamilton DL. The effect of copper deficiency on the immune response in mice. Drug Nutr Interact. (1987)
- Koller LD, et al. Immune dysfunction in rats fed a diet deficient in copper. Am J Clin Nutr. (1987)
- Percival SS1. Copper and immunity. Am J Clin Nutr. (1998)
- Williams DM. Copper deficiency in humans. Semin Hematol. (1983)
- Dietary Reference Intake for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.
- Squitti R1, Siotto M2, Polimanti R3. Low-copper diet as a preventive strategy for Alzheimer's disease. Neurobiol Aging. (2014)
- Barnard ND1, et al. Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. Neurobiol Aging. (2014)
- Turnlund JR1, et al. Copper absorption and retention in young men at three levels of dietary copper by use of the stable isotope 65Cu. Am J Clin Nutr. (1989)
- Cunnane SC, Horrobin DF, Manku MS. Contrasting effects of low or high copper intake on rat tissue lipid essential fatty acid composition. Ann Nutr Metab. (1985)
- Saltzman E1, Karl JP. Nutrient deficiencies after gastric bypass surgery. Annu Rev Nutr. (2013)
- Kumar N1, McEvoy KM, Ahlskog JE. Myelopathy due to copper deficiency following gastrointestinal surgery. Arch Neurol. (2003)
- Plantone D1, et al. PPIs as possible risk factor for copper deficiency myelopathy. J Neurol Sci. (2015)
- Sakai N1, et al. Marginal copper deficiency increases liver neutrophil accumulation after ischemia/reperfusion in rats. Biol Trace Elem Res. (2011)
- Li Y1, et al. Marginal dietary copper restriction induces cardiomyopathy in rats. J Nutr. (2005)
- Wildman RE1, et al. Marginal copper-restricted diets produce altered cardiac ultrastructure in the rat. Proc Soc Exp Biol Med. (1995)
- Schuschke DA1, et al. Relationship between dietary copper concentration and acetylcholine-induced vasodilation in the microcirculation of rats. Biofactors. (1999)
- Schuschke LA1, et al. Hemostatic mechanisms in marginally copper-deficient rats. J Lab Clin Med. (1995)
- Schuschke DA1, et al. Cyclooxygenase-2 is upregulated in copper-deficient rats. Inflammation. (2009)
- Lentsch AB1, et al. Augmented metalloproteinase activity and acute lung injury in copper-deficient rats. Am J Physiol Lung Cell Mol Physiol. (2001)
- Schuschke DA1, et al. Tissue-specific ICAM-1 expression and neutrophil transmigration in the copper-deficient rat. Inflammation. (2002)
- Elsherif L1, et al. Congestive heart failure in copper-deficient mice. Exp Biol Med (Maywood). (2003)
- Davidson J1, Medeiros DM, Hamlin RL. Cardiac ultrastructural and electrophysiological abnormalities in postweanling copper-restricted and copper-repleted rats in the absence of hypertrophy. J Nutr. (1992)
- Elsherif L1, et al. Regression of dietary copper restriction-induced cardiomyopathy by copper repletion in mice. J Nutr. (2004)
- Plantone D, et al. Copper deficiency myelopathy: A report of two cases. J Spinal Cord Med. (2014)
- Kumar N1, Gross JB Jr, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology. (2004)
- Kumar N1, et al. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology. (2006)
- Imani S1, et al. Changes in copper and zinc serum levels in women wearing a copper TCu-380A intrauterine device. Eur J Contracept Reprod Health Care. (2014)
- Rodrigues da Cunha AC1, Dorea JG, Cantuaria AA. Intrauterine device and maternal copper metabolism during lactation. Contraception. (2001)
- Gollan GL. Studies on the nature of complexes formed by copper with human alimentary secretions and their influence on copper absorption in the rat. Clin Sci Mol Med. (1975)
- VANCAMPEN DR, MITCHELL EA. ABSORPTION OF CU-64, ZN-65, MO-99, AND FE-59 FROM LIGATED SEGMENTS OF THE RAT GASTROINTESTINAL TRACT. J Nutr. (1965)
- Fields M, et al. Contrasting effects of the stomach and small intestine of rats on copper absorption. J Nutr. (1986)
- Brewer GJ. Risks of copper and iron toxicity during aging in humans. Chem Res Toxicol. (2010)
- Hill GM, et al. Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci. (1986)
- Murgia C1, et al. Cloning, expression, and vesicular localization of zinc transporter Dri 27/ZnT4 in intestinal tissue and cells. Am J Physiol. (1999)
- Árus D1, et al. A comparative study on the possible zinc binding sites of the human ZnT3 zinc transporter protein. Dalton Trans. (2013)
- Arredondo M1, et al. DMT1, a physiologically relevant apical Cu1+ transporter of intestinal cells. Am J Physiol Cell Physiol. (2003)
- Espinoza A1, et al. Iron, copper, and zinc transport: inhibition of divalent metal transporter 1 (DMT1) and human copper transporter 1 (hCTR1) by shRNA. Biol Trace Elem Res. (2012)
- Gao S1, et al. Amino acid facilitates absorption of copper in the Caco-2 cell culture model. Life Sci. (2014)
- Wapnir RA. Copper absorption and bioavailability. Am J Clin Nutr. (1998)
- Turnlund JR, et al. A stable isotope study of copper absorption in young men: effect of phytate and alpha-cellulose. Am J Clin Nutr. (1985)
- Hall AC, Young BW, Bremner I. Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat. J Inorg Biochem. (1979)
- Fischer PW, Giroux A, L'Abbé MR. The effect of dietary zinc on intestinal copper absorption. Am J Clin Nutr. (1981)
- Kumar KS1, Dayananda S, Subramanyam C. Copper alone, but not oxidative stress, induces copper-metallothionein gene in Neurospora crassa. FEMS Microbiol Lett. (2005)
- Oestreicher P, Cousins RJ. Copper and zinc absorption in the rat: mechanism of mutual antagonism. J Nutr. (1985)
- Davies NT, Nightingale R. The effects of phytate on intestinal absorption and secretion of zinc, and whole-body retention of Zn, copper, iron and manganese in rats. Br J Nutr. (1975)
- Greger JL, Snedeker SM. Effect of dietary protein and phosphorus levels on the utilization of zinc, copper and manganese by adult males. J Nutr. (1980)
- Sandstead HH. Copper bioavailability and requirements. Am J Clin Nutr. (1982)
- MOORE T, et al. COPPER DEFICIENCY IN RATS FED UPON RAW MEAT. Br J Nutr. (1964)
- Ferenci P. Wilson's disease. Clin Liver Dis. (1998)
- Brewer GJ1, et al. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res. (2009)
- Yüce A1, et al. Wilson's disease patients with normal ceruloplasmin levels. Turk J Pediatr. (1999)
- Squitti R1, et al. Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis. (2011)
- Squitti R1, Polimanti R. Copper phenotype in Alzheimer's disease: dissecting the pathway. Am J Neurodegener Dis. (2013)
- Linder MC1, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr. (1996)
- Hassan W1, et al. Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions. Curr Neuropharmacol. (2014)
- Sharonova IN1, Vorobjev VS, Haas HL. High-affinity copper block of GABA(A) receptor-mediated currents in acutely isolated cerebellar Purkinje cells of the rat. Eur J Neurosci. (1998)
- Kim H1, Macdonald RL. An N-terminal histidine is the primary determinant of alpha subunit-dependent Cu2+ sensitivity of alphabeta3gamma2L GABA(A) receptors. Mol Pharmacol. (2003)
- Kalueff AV1, Nutt DJ. Role of GABA in anxiety and depression. Depress Anxiety. (2007)
- Islam MR1, et al. Comparative analysis of serum zinc, copper, manganese, iron, calcium, and magnesium level and complexity of interelement relations in generalized anxiety disorder patients. Biol Trace Elem Res. (2013)
- Russo AJ1. Decreased zinc and increased copper in individuals with anxiety. Nutr Metab Insights. (2011)
- Schlegel-Zawadzka M1, et al. Is serum copper a "trait marker" of unipolar depression? A preliminary clinical study. Pol J Pharmacol. (1999)
- Chang MY1, Tseng CH, Chiou YL. The plasma concentration of copper and prevalence of depression were positively correlated in shift nurses. Biol Res Nurs. (2014)
- Crayton JW1, Walsh WJ. Elevated serum copper levels in women with a history of post-partum depression. J Trace Elem Med Biol. (2007)
- Russo AJ1. Analysis of plasma zinc and copper concentration, and perceived symptoms, in individuals with depression, post zinc and anti-oxidant therapy. Nutr Metab Insights. (2011)
- Klevay LM. Cardiovascular disease from copper deficiency--a history. J Nutr. (2000)
- Allen KG, Klevay LM. Copper: an antioxidant nutrient for cardiovascular health. Curr Opin Lipidol. (1994)
- Reunanen A, Knekt P, Aaran RK. Serum ceruloplasmin level and the risk of myocardial infarction and stroke. Am J Epidemiol. (1992)
- Ford ES. Serum copper concentration and coronary heart disease among US adults. Am J Epidemiol. (2000)
- Cooper GJ, et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. Diabetologia. (2009)
- Lind PM, Olsén L, Lind L. Elevated circulating levels of copper and nickel are found in elderly subjects with left ventricular hypertrophy. Ecotoxicol Environ Saf. (2012)
- DiSilvestro RA, et al. A randomized trial of copper supplementation effects on blood copper enzyme activities and parameters related to cardiovascular health. Metabolism. (2012)
- Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. (2005)
- Bügel S, et al. Effect of copper supplementation on indices of copper status and certain CVD risk markers in young healthy women. Br J Nutr. (2005)
- Bagheri B, et al. Serum level of copper in patients with coronary artery disease. Niger Med J. (2015)
- Iskra M, Majewski W, Piorunska-Stolzmann M. Modifications of magnesium and copper concentrations in serum and arterial wall of patients with vascular diseases related to ageing, atherosclerosis and aortic aneurysm. Magnes Res. (2002)
- Russo C, et al. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens. (1998)
- Jones AA, et al. Copper supplementation of adult men: effects on blood copper enzyme activities and indicators of cardiovascular disease risk. Metabolism. (1997)
- Rojas-Sobarzo L, et al. Copper supplementation at 8 mg neither affects circulating lipids nor liver function in apparently healthy Chilean men. Biol Trace Elem Res. (2013)
- Turley E, et al. Copper supplementation in humans does not affect the susceptibility of low density lipoprotein to in vitro induced oxidation (FOODCUE project). Free Radic Biol Med. (2000)
- Keil HL, Nelson VE. THE RÔLE OF COPPER IN CARBOHYDRATE METABOLISM. J Biol Chem. (1934)
- Kazi TG1, et al. Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus patients. Biol Trace Elem Res. (2008)
- Ekmekcioglu C1, et al. Concentrations of seven trace elements in different hematological matrices in patients with type 2 diabetes as compared to healthy controls. Biol Trace Elem Res. (2001)
- Walter RM Jr1, et al. Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care. (1991)
- Savu O1, et al. Increase in total antioxidant capacity of plasma despite high levels of oxidative stress in uncomplicated type 2 diabetes mellitus. J Int Med Res. (2012)
- Aguilar MV1, et al. Plasma mineral content in type-2 diabetic patients and their association with the metabolic syndrome. Ann Nutr Metab. (2007)
- Williams NR1, et al. Plasma, granulocyte and mononuclear cell copper and zinc in patients with diabetes mellitus. Analyst. (1995)
- Viktorínová A1, et al. Altered metabolism of copper, zinc, and magnesium is associated with increased levels of glycated hemoglobin in patients with diabetes mellitus. Metabolism. (2009)
- Wills NK1, et al. Copper and zinc distribution in the human retina: relationship to cadmium accumulation, age, and gender. Exp Eye Res. (2008)
- Behndig A1, et al. Superoxide dismutase isoenzymes in the human eye. Invest Ophthalmol Vis Sci. (1998)
- Gahlot DK, Ratnakar KS. Effect of experimentally induced chronic copper toxicity on retina. Indian J Ophthalmol. (1981)
- Wills NK1, et al. Cadmium accumulation in the human retina: effects of age, gender, and cellular toxicity. Exp Eye Res. (2008)
- Zampatti S1, et al. Review of nutrient actions on age-related macular degeneration. Nutr Res. (2014)
- Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials. (1999)
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. (2001)
- Sin HP1, Liu DT, Lam DS. Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration. Acta Ophthalmol. (2013)
- Gordon SA1, et al. Impaired deformability of copper-deficient neutrophils. Exp Biol Med (Maywood). (2005)
- Lominadze D1, et al. Proinflammatory effects of copper deficiency on neutrophils and lung endothelial cells. Immunol Cell Biol. (2004)
- Wagner D1, et al. Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates pathogen-induced microenvironments within the host cell's endosomal system. J Immunol. (2005)
- Babu U1, Failla ML. Respiratory burst and candidacidal activity of peritoneal macrophages are impaired in copper-deficient rats. J Nutr. (1990)
- Suttle NF1, Jones DG. Recent developments in trace element metabolism and function: trace elements, disease resistance and immune responsiveness in ruminants. J Nutr. (1989)
- Leary SC1, Winge DR. The Janus face of copper: its expanding roles in biology and the pathophysiology of disease. Meeting on Copper and Related Metals in Biology. EMBO Rep. (2007)
- White C1, et al. A role for the ATP7A copper-transporting ATPase in macrophage bactericidal activity. J Biol Chem. (2009)
- Pyo HK1, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. (2007)
- Kil MS, Kim CW, Kim SS. Analysis of serum zinc and copper concentrations in hair loss. Ann Dermatol. (2013)
- Bhat YJ1, et al. Trace element levels in alopecia areata. Indian J Dermatol Venereol Leprol. (2009)
- Ozturk P1, et al. BMI and levels of zinc, copper in hair, serum and urine of Turkish male patients with androgenetic alopecia. J Trace Elem Med Biol. (2014)
- Turok DK1, et al. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates. Contraception. (2014)
- Farr G1, Amatya R. Contraceptive efficacy of the Copper T380A and the Multiload Cu250 IUD in three developing countries. Adv Contracept. (1994)
- Yu J1, et al. Comparative study on contraceptive efficacy and clinical performance of the copper/low-density polyethylene nanocomposite IUD and the copper T220C IUD. Contraception. (2008)
- Andrade AT1, et al. Consequences of uterine blood loss caused by various intrauterine contraceptive devices in South American women. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. (1988)
- Sivin I1, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol. (1992)
- Godfrey EM1, et al. Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. Contraception. (2013)
- Bush AI1, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics. (2008)
- Bucossi S1, et al. Copper in Alzheimer's disease: a meta-analysis of serum,plasma, and cerebrospinal fluid studies. J Alzheimers Dis. (2011)
- Brewer GJ1. The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer's disease. J Am Coll Nutr. (2009)
- Madarić A1, Ginter E, Kadrabová J. Serum copper, zinc and copper/zinc ratio in males: influence of aging. Physiol Res. (1994)
- Vasudevaraju P1, et al. New evidence on iron, copper accumulation and zinc depletion and its correlation with DNA integrity in aging human brain regions. Indian J Psychiatry. (2010)
- Mao X1, et al. The effects of chronic copper exposure on the amyloid protein metabolisim associated genes' expression in chronic cerebral hypoperfused rats. Neurosci Lett. (2012)
- Ceccom J1, et al. Copper chelator induced efficient episodic memory recovery in a non-transgenic Alzheimer's mouse model. PLoS One. (2012)
- White AR1, et al. The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci. (1999)
- Wang H1, et al. The distribution profile and oxidation states of biometals in APP transgenic mouse brain: dyshomeostasis with age and as a function of the development of Alzheimer's disease. Metallomics. (2012)
- Yoshiike Y1, et al. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J Biol Chem. (2001)
- Huang X1, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry. (1999)
- Dikalov SI1, Vitek MP, Mason RP. Cupric-amyloid beta peptide complex stimulates oxidation of ascorbate and generation of hydroxyl radical. Free Radic Biol Med. (2004)
- Huang X1, et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem. (1999)
- Barnham KJ1, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. (2004)
- Dai XL1, Sun YX, Jiang ZF. Cu(II) potentiation of Alzheimer Abeta1-40 cytotoxicity and transition on its secondary structure. Acta Biochim Biophys Sin (Shanghai). (2006)
- Squitti R1, Polimanti R. Copper hypothesis in the missing hereditability of sporadic Alzheimer's disease: ATP7B gene as potential harbor of rare variants. J Alzheimers Dis. (2012)
- Squitti R1, et al. Linkage disequilibrium and haplotype analysis of the ATP7B gene in Alzheimer's disease. Rejuvenation Res. (2013)
- Aschner M1, West AK. The role of MT in neurological disorders. J Alzheimers Dis. (2005)
- Sharma S1, Ebadi M2. Significance of metallothioneins in aging brain. Neurochem Int. (2014)
- Palmiter RD1. Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. Proc Natl Acad Sci U S A. (1994)
- Heuchel R1, et al. The transcription factor MTF-1 is essential for basal and heavy metal-induced metallothionein gene expression. EMBO J. (1994)
- Klaassen CD1, Liu J, Choudhuri S. Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol. (1999)
- Aschner M1, et al. Metallothioneins: mercury species-specific induction and their potential role in attenuating neurotoxicity. Exp Biol Med (Maywood). (2006)
- Willis MS1, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. (2005)
- Afrin LB1. Fatal copper deficiency from excessive use of zinc-based denture adhesive. Am J Med Sci. (2010)
- Nations SP1, et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology. (2008)
- Prodan CI1, et al. CNS demyelination associated with copper deficiency and hyperzincemia. Neurology. (2002)
- Prodan CI1, Holland NR. CNS demyelination from zinc toxicity. Neurology. (2000)
- Intestinal absorption of copper: Effect of amino acids.
- Baker DH, Czarnecki-Maulden GL. Pharmacologic role of cysteine in ameliorating or exacerbating mineral toxicities. J Nutr. (1987)
- Van Campen D, Gross E. Influence of ascorbic acid on the absorption of copper by rats. J Nutr. (1968)
- Aoyagi S1, Baker DH. Copper-amino acid complexes are partially protected against inhibitory effects of L-cysteine and L-ascorbic acid on copper absorption in chicks. J Nutr. (1994)